Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Plos One|February 23, 2017
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trialMandy Kader Konde, Darren P Baker, Fode Amara Traore, et al.Molecular and Cellular Biology|October 7, 2009
Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signalingJianghuai Liu, Lucas P Carvalho, Sabyasachi Bhattacharya, et al.The Journal of Biological Chemistry|October 18, 2012
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responsesBhumika Sharma, Sonali Joshi, Antonella Sassano, et al.Protein Science : a Publication of the Protein Society|January 7, 2010
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinasesDouglas J Marcotte, Yu-Ting Liu, Robert M Arduini, et al.Bioconjugate Chemistry|January 19, 2006
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis modelDarren P Baker, Edward Y Lin, Kochung Lin, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 15, 2010
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosisDarren P Baker, Robert Blake Pepinsky, Margot Brickelmaier, et al.Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|November 12, 2016
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft ModelsAntonio Boccia, Cyrus Virata, Daniel Lindner, et al.Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and managementAdam Cuker, Ann D Bass, Congor Nadj, et al.Pageof 7